In the second half of 2021 venture financing deals increased significantly by 67.7% from the same period in 2020.

This marks an acceleration in growth from the 4.3% decrease in deals seen from the first six months of 2020 to the same period in 2021.

During this time, the region that saw the biggest increase in the number of deals was North America.

From the second half of 2020 to the second half of 2021, the largest regional increase in deals was also seen in North America.

The region saw a 76.5% increase in deals.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData

During second half of 2021, venture financing deals accounted for 19.3% of deals taking place in the sector. This represents an increase from the figure of 3.4% in second half of 2020.

GlobalData's deals database is a comprehensive repository that looks at mergers, acquisitions, venture financing, equity offerings, asset transactions, partnerships and debt offerings taking place daily between thousands of companies across the world.

The database details key deal information, such as deal summary, deal rationale, deal financials, parties involved, advisors and deal payment modes.

By tracking the proportion of various types of deals in each sector we can gauge which sectors are seeing growth and where others are struggling.

The highest value venture financing deal that took place in 2021 (where the deal value was known) was the $200 million secured by Stemirna Therapeutics.

The database states that the rationale behind this deal was as follows: "Stemirna Therapeutics intends to use the proceeds to finance clinical trials and production of its COVID-19 vaccine candidate."